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Abstract
Leishmaniasis is a vector-born chronic infectious disease caused by a group of protozoan parasites of the genus Leishmania. Whereas most
immunocompetent individuals will not develop disease after Leishmania infection, immunosuppression is a well-established risk factor for
disease. The most severe form is visceral leishmaniasis (VL), which is typically fatal if untreated. Whereas human immunodeﬁciency virus
(HIV) co-infection (VL–HIV) was initially mainly reported from southern Europe, it is now emerging in other regions, including East Africa,
India, and Brazil. VL has also been found in a wide range of non-HIV-related immunosuppressive states, mainly falling under the realm of
transplantation medicine, rheumatology, haematology, and oncology. Clinical presentation can be atypical in immunosuppressed individuals,
being easily misdiagnosed or mistaken as a ﬂare-up of the underlying disease. The best diagnostic approach is the combination of
parasitological and serological or molecular methods. Liposomal amphotericin B is the drug of choice. Treatment failure and relapse rates
are particularly high in cases of HIV co-infection, despite initiation of antiretroviral treatment. Primary prophylaxis is not recommended, but
secondary prophylaxis is recommended when the patient is immunosuppressed. Cutaneous leishmaniasis can have a number of particular
features in individuals with immunosuppression, especially if severe, including parasite dissemination, clinical polymorphism with atypical and
often more severe clinical forms, and even visceralization. Mucosal leishmaniasis is more common. Treatment of cutaneous and mucosal
leishmaniasis can be challenging, and systemic treatment is more often indicated. With globally increased travel and access to advanced
medical care in developing countries, the leishmaniasis burden in immunosuppressed individuals will probably continue to rise, warranting
increased awareness and enhanced surveillance systems.
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Introduction
Leishmaniasis is a chronic infectious disease caused by a
group of protozoan parasites of the genus Leishmania. The
parasites are transmitted to humans via the bite of phlebo-
tome sandﬂies, and predominantly target reticuloendothelial
cells. Leishmaniasis can present with a spectrum of clinical
manifestations (Table 1) [1]. Visceral leishmaniasis (VL; kala
azar) is a potentially fatal condition characterized by hepato-
splenomegaly, chronic fever, weight loss, and pancytopenia
[2]. Typically, VL is classiﬁed as zoonotic, caused by
Leishmania infantum (syn. Leishmania chagasi in South Amer-
ica), with the dog as the main reservoir, or anthroponotic,
caused by Leishmania donovani, mainly found in East Africa and
the Indian subcontinent [1–3]. Cutaneous leishmaniasis (CL)
is more widely distributed [3,4]. Ulcerative skin lesions
occurring at the site of the bite of the sandﬂy constitute the
most common cutaneous manifestation (localized CL).
Although it often heals spontaneously, CL typically leaves
scars and can be disﬁguring and stigmatizing. There are
several more rare forms, such as diffuse CL, which is often
difﬁcult to treat. Mucosal leishmaniasis (ML) or mucocutane-
ous leishmaniasis (MCL) refers to an often destructive form
with mucosal inﬂammation, which has been mainly reported
in association with Leishmania brazilienzis [4,5], but also in the
Old World [6]. The most recent global estimates suggest
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approximately 0.2–0.4 million annual cases of VL and approx-
imately 1 million cases of CL [3].
Whereas autochthonous leishmaniasis remains relatively
rare in Europe, being mainly conﬁned to southern Europe
(estimated annual VL incidence of 340–510 cases), imported
leishmaniasis is now being increasingly reported [7–12]. As
demonstrated by the spread of L. infantum in Italy and the
recent outbreak in Madrid [13], leishmaniasis has the potential
to further emerge or re-emerge within Europe, through
spread of the current species (L. infantum and Leishmania
tropica) because of climate change, the introduction of exotic
Leishmania species because of international travel and immi-
gration, and the increased number of immunosuppressed
people [14,15]. Immunosuppression is one of the strongest
risk factors for overt clinical disease, and can also alter disease
presentation and treatment response. Although immunosup-
pression has historically been mainly observed in human
immunodeﬁciency virus (HIV)-infected patients, non-HIV-
related immunosuppressive conditions are becoming increas-
ingly prevalent globally, mainly because of better medical care
of patients with chronic illnesses and the therapeutic use of
immunosuppressive drugs. In this review, we focus on the
challenges in terms of diagnosis, prevention and treatment of
leishmaniasis in immunosuppressed individuals. Given its
life-threatening potential and the strong interaction with
immunosuppression, the main focus will be on VL.
Epidemiology and Risk Factors
The epidemiological and clinical impact of immunosuppres-
sion on VL was most strikingly illustrated by the effect of the
HIV epidemic in VL-endemic countries in southern Europe,
with HIV contributing to the re-emergence of VL. By early
2000, almost 2000 cases of VL–HIV (predominantly in
intravenous drug users) had been notiﬁed, with 50–60% of
all VL cases being HIV-co-infected at some point [16]. It is of
interest that an anthroponotic transmission cycle for L. infan-
tum could be demonstrated, whereby parasites were trans-
mitted among intravenous drug users via the shared use of
needles and syringes [17]. Moreover, some studies demon-
strated that L. infantum could be more readily detected in
peripheral blood in HIV-infected patients, suggesting
increased infectivity, and possibly also indicating an overall
higher parasite load. Fortunately, with the wide-scale intro-
duction of highly active antiretroviral therapy (HAART), a
gradual decline in VL incidence has been observed over the
last decade [18,19]. Currently, the burden of VL–HIV
co-infection is most pronounced in some regions in East
Africa, such as north-western Ethiopia, where between 20–
40% of individuals with VL are co-infected with HIV [18].
The problem also seems to be emerging in India and Brazil
[18,20–23].
In Europe, where individuals with VL–HIV co-infection are
often intravenous drug users, parasites causing VL in
HIV-infected individuals have been found to be more diverse,
with higher enzymatic polymorphism, than those in the general
population [16]. In some HIV-co-infected cases, non-human
pathogenic trypanosomatids have been isolated [24,25]. The
extent and signiﬁcance of these observations at the global level
are currently not well deﬁned. It is of interest that a recent
study from Italy suggested an apparent reversal of the initial
increase in zymodeme diversity concurrent with HAART
introduction [26].
TABLE 1. Aetiology, burden, clinical forms and treatment of leishmaniasis
Aetiology/main geographya High-burden countries Clinical presentation/forms Main treatment options
VL
Leishmania infantum (syn. Leishmania chagasi):
Mediterrean basin, Latin America, Middle East,
Asia (China) (zoonotic transmission)
Top six countries (90% of global
burden):
India, Nepal, Bangladesh, Brazil,
South Sudan, Ethiopia
Persistent fever, (hepato)splenomegaly
and weight loss
Pancytopenia, hyperglobulinaemia
Antimonials
Conventional amphoterin B
Liposomal amphoterin B
Miltefosineb
Paromomycinb
Leishmania donovani:
Indian subcontinent (anthroponotic), East Africa
(mainly anthroponotic; possibly zoonotic
transmission)
CL and ML
New World CL: (South and Central America)
Leishmania braziliensis, Leishmania panamensis,
Leishmania peruviana, Leishmania guyanensis,
Leishmania colombiensis, Leishmania amazonensis,
Leishmania mexicana, Leishmania venezuelensis
Top 10 countries (70–75% of
global burden): Afghanistan, Iran,
Syria, Algeria, Ethiopia,
North Sudan, Colombia, Brazil,
Costa Rica, Peru
Localized CL rare forms:
Diffuse CL
Disseminated CL
Leishmaniasis recidivans cutis
ML
Local treatment:
Intralesional antimonials
Topical paromomycin
Cryotherapy/thermotherapy
Systemic treatment:
Antimonials
Conventional and liposomal
amphoterin B
Miltefosineb
Paromomycinb
Ketoconazole/ﬂuconazole
Pentamidine
Old World CL:
Leishmania major (north-eastern Africa, Middle
East, Asia); Leishmania tropica (Asia, North Africa,
Middle East); Leishmania aethiopica (Ethiopia);
L. infantum (see above)
CL, cutaneous leishmaniasis; ML, mucosal leishmaniasis; VL, visceral leishmaniasis.
aSome more exceptional species (e.g. Leishmania killicki, Leishmania pifanoi, and Leishmania garnhami) are not included.
bDifﬁcult to obtain/limited availability in most Western countries.
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Non-HIV-related immunosuppressive conditions are now
attracting increasing attention. This group comprises a heter-
ogeneous collection of medical conditions that hamper VL
immunological control and promote either reactivation from a
latent infection, or failure to control a new infection. Broadly
speaking, the vast majority of reported non-HIV-related
immunosuppressive conditions fall under the realm of trans-
plantation medicine, rheumatology, haematology, and oncol-
ogy. VL has been reported after many different types of organ
transplantation [27–36]. Antinori et al. provided a detailed
review of leishmaniasis in organ transplant recipients, and
reported on 79 cases by 2008, a four-fold increase since the
early 1990s [31]. Most (77%) were diagnosed after renal
transplantation (which is also the most commonly performed
procedure). VL was most frequently observed (86% of cases),
followed by MCL, and CL was observed more rarely. In this
study, the time of occurrence of leishmaniasis tended to vary
with the organ concerned, with median times of 6 months
after liver transplantation and 19 months after renal trans-
plantation. Several VL cases have been diagnosed after
haematopoietic stem cell/bone marrow transplantation [37–
40]. With the number of organ or tissue transplantations
growing globally, and travel to and from VL-endemic regions
becoming more common, the burden will most likely increase
[40–42]. Given the lack of detailed prospective studies, data on
the risk and determinants of VL across the different types of
transplantation and immunosuppressive drugs used are limited.
In the ﬁeld of rheumatology, VL has been reportedly
associated with the use of various immunosuppressive drugs,
such as azathioprine, methotrexate, steroids, cyclosporine, and
cyclophosphamide (Table 2) [43–49]. The introduction of
tumour necrosis factor-a (TNF-a) antagonist drugs has
received much attention recently [50]. Whereas initial reports
mainly focused on the risk of tuberculosis following the use of
these drugs, there are now also a substantial number (several
tens) of reports on leishmaniasis, typically occurring after many
months of use [51–54]. Although the type was VL in the
majority of cases, CL and MCL were also observed. Current
data suggest a higher risk in patients receiving anti-TNF-a
monoclonal antibodies (such as inﬂiximab) than in patients
treated with TNF-a receptor constructs, such as etanercept
[51]. As a global surveillance and reporting system is currently
lacking, the current numbers are most likely underestimated. A
European adverse event reporting system to detect rare
infections associated with immunosuppressive and immuno-
modulatory therapies has been called for [55]. There have also
been cases of leishmaniasis in patients receiving chronic steroid
treatment for several indications, including asthma, sarcoidosis,
and myasthenia gravis [56–58], and receiving other immuno-
suppressive drugs for a range of conditions, including inﬂam-
matory bowel disease [59]. Several cancer-related cases
(mainly haematological malignancies) of VL have been
reported, associated with the use of various chemotherapeutic
regimens or monoclonal antibodies [60,61]. Reports of
leishmaniasis in patients with primary immunodeﬁciencies are
rare.
That immunosuppressive conditions pose a real challenge in
VL-endemic regions is illustrated by the recent L. infantum
community outbreak in Madrid [13]. Among the 446 cases
detected between July 2009 and December 2012, 15.2%
(n = 68) had immunosuppressive conditions, mostly non-
HIV-related. Overall, 31.3% of VL cases and 6.3% of CL cases
were diagnosed in immunosuppressed individuals.
Immunology
The immunology and pathogenesis of leishmaniasis are com-
plex; see a number of recent reviews for detailed information
[62–64]. In the majority of individuals, Leishmania infection
does not progress to overt disease. In some highly endemic
areas, up to 30% of the inhabitants are asymptomatically
infected [65]. Although the determinants of progression to
disease after primary infection are only partly understood,
parasitic virulence, nutritional status, age and host genetic and
response factors are known to contribute [63,66]. Control of
TABLE 2. Selected reports on cases of visceral leishmaniasis
found in non-human immunodeﬁciency virus-related immu-
nosuppressive conditionsa
Medical condition
Immunosuppressive
drugs Reference
Transplantation
Bone marrow/
haematopoietic stem cells
Various, including
steroids, cyclosporine,
azathioprine, tacrolimus,
and mycophenolate
mofetil
[37–40,183]
Solid organ: mainly kidney;
more rarely liver, heart, lung,
and kidney–pancreas
[27–36,184]
Rheumatological/connective tissue diseases/vasculitis
Rheumatoid arthritis Various, including
steroids, methotrexate,
cyclophosphamide,
anti-TNF-a agents
[44,46,47,51,98,
99,185–189]
Systemic lupus erythematosus [43,45,99]
Wegener’s granulomatosis [48]
Idiopathic juvenile arthritis [80,190]
Ankylosing spondylitis [149,190]
Giant cell arthritis [149]
Psoriatic arthritis [51, 111, 191]
Other chronic inﬂammatory or iatrogenic immunosuppressive conditions
Asthma Steroids [56]
Asthma/dermatitis Steroids [168]
COPD Steroids [58]
Cheilitis granulomatosa Steroids [56]
Ulcerative colitis Azathioprine/cyclosporine [59]
Sarcoidosis Steroids [57]
Myasthenia gravis Steroids [56]
Oncology [61]
Haematological malignancies Various (chemotherapy) [60,192–195]
Solid tumours [61]
COPD, chronic obstructive pulmonary disease; TNF-a, tumour necrosis factor-a.
aNon-exhaustive, with priority given to more recent or particularly interesting
cases.
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infection relies on activated, leishmanicidal macrophages and
an intact speciﬁc T-helper cell type 1 (Th1) response. A
positive leishmanin skin test result is assumed to indicate
cell-mediated immunity. Overt disease is associated with a
mixed Th1/T-helper cell type 2 (Th2) response. High levels of
regulatory T-cells are thought to contribute to the pro-
nounced immunosuppression seen during VL [1]. Important
proinﬂammatory cytokines mediating an effective Th1
response, enhancing the leishmanicidal capacity of macrophag-
es, include interferon-c and TNF-a. Usually, viable parasites
persist after primary infection, and this can potentially lead to
reactivation and disease if immunosuppression occurs [18,67].
Whereas CD4 T-cell depletion and skewing towards a Th2
immune response are hallmarks of HIV infection, immune
alterations occur at multiple levels of the innate and adaptive
immune system, including macrophage dysfunction [68].
Importantly, HIV and Leishmania co-localize and interact in
the same host cell (macrophages and dendritic cells), mutually
reinforcing each other’s pathogenic effects and further com-
promising macrophage function [69]. Clinical data suggest that
Leishmania co-infection leads to increased immune activation in
HIV-infected patients, which persists even after apparently
successful VL treatment or after initiation of HAART, poten-
tially leading to further HIV disease progression and a poor
CD4 cell count response [70–72]. Whereas most VL–
HIV-co-infected patients in Europe present with CD4 cell
counts of <200 cells/mL at VL diagnosis [15,68], studies in
Ethiopia—where L. donovani is prevalent—have demonstrated
the occurrence of VL with higher CD4 cell counts [69,70].
The non-HIV-related immunosuppressive conditions pre-
disposing to VL constitute a heterogeneous group of different
medical conditions, mostly iatrogenic via immune-ablative
chemotherapy, and immunosuppressive or immunomodula-
tory drugs. For most, different layers of the immune system
are affected, and the precise mechanism behind the VL risk has
not been well deﬁned. Although most of these conditions will
affect other cells and molecules, T-cell lymphocytes are usually
signiﬁcantly affected, through different mechanisms, including
lymphocyte depletion, interference with maturation, cell
cycling and co-stimulation, and induction of tolerance, thereby
altering the mechanisms of defence against intracellular
microorganisms [73]. In this scenario, VL can develop because
of reactivation from a previous dormant infection, a de novo
infection when the individual is residing in a VL-endemic area,
and very rarely iatrogenic infection via an infected donor organ
or blood product [31]. Reactivation is thought to be the most
common mechanism causing transplant-related VL in endemic
areas, especially those cases occurring relatively early after the
intervention, when the immunosuppression is most pro-
nounced [74,75].
Diagnostic Aspects
Clinical presentation and diagnostic challenges
Although most cases of VL–HIV co-infection will show the
typical VL signs and symptoms, atypical presentations occur in
those who are severely immunosuppressed. Most often, these
will consist of (localized) detection of parasites in abnormal
tissues such as the intestine, oral cavity, skin, and lung tissue.
Skin manifestations appear to be more frequent, and can occur
before, during or after the VL episode [76–83]. However,
parasites have also been found in healthy skin or coincidentally
in other skin pathologies and tattoos [84]. The current data do
not allow a reliable comparison with the clinical presentation
in individuals with non-HIV-related immunosuppression, but
atypical presentations have been reported, and the disease
manifestations in those with HIV-related and non-HIV-related
immunosuppression are probably similar [85]. In renal patients,
VL can lead to graft dysfunction [31].
Post-kala azar dermal leishmaniasis appears to be more
frequent in individuals with immunosuppression [86]. Whereas
post-kala azar dermal leishmaniasis is usually not seen with
L. infantum, it has been described in HIV patients [87–92], in
some cases being attributed to the immune reconstitution
inﬂammatory syndrome (IRIS) and non-HIV-related immuno-
suppression.
Symptoms and signs of VL can overlap with those of various
conditions, including opportunistic infections. Disseminated
mycobacterial infections, lymphoma and disseminated histo-
plasmosis should be considered in the differential diagnosis.
Laboratory abnormalities are also diverse and non-speciﬁc, and
include, besides pancytopenia, increases in acute-phase
response proteins (C-reactive protein, sedimentation rate,
and ferritin). VL is also characterized by overactivation of
B-cells, leading to pronounced polyclonal hypergammaglobu-
linaemia, and sometimes producing positive indirect Coombs
test results, and detectable levels of anti-nuclear antibodies,
anti-dsDNA antibodies, anti-smooth muscle antibodies,
anti-cardiolipin antibodies, anti-cyclic citrullinated peptide
antibodies, and IgM rheumatoid factor [93]. Activation of the
coagulation cascade (increased D-dimer levels, decreased
ﬁbrinogen levels, prolonged prothrombin time, and prolonged
activated partial thromboplastin time), circulating immune
complexes, low complement levels and cryoglobulinaemia have
also been observed [94–96]. There are several reports of VL
resembling or initially being misdiagnosed as an autoimmune
disease (including systemic lupus erythematosus and rheuma-
toid arthritis), or as a ﬂare-up of the underlying disease [43–
49,97–99], and this can potentially lead to inappropriate
increases in immunosuppressive drug use [43–45,49,100] or
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even unnecessary splenectomy [98]. There have been cases of
rheumatoid arthritis in patients receiving anti-TNF-a therapy,
whereby VL was misdiagnosed as drug-induced lupus
[101,102]. Similarly, the combination of pancytopenia, spleno-
megaly and abnormalities on bone marrow biopsy has led to
misdiagnosis as (mainly haematological) malignancies
[61,103,104]. The haemophagocytic syndrome also has sev-
eral features that are similar to those of VL (including fever
with pancytopenia, hepatosplenomegaly and a pronounced
pro-inﬂammatory cytokine burst), but VL can also act as an
infectious trigger for a secondary haemophagocytic syndrome,
with pronounced haemophagocytosis being seen in the bone
marrow [105,106]. Other reports of challenging VL diagnosis
include presentation as a monoclonal gammopathy [107] and
autoimmune hepatitis [100,108,109].
Laboratory diagnosis
Microscopy for parasite detection in different tissue samples is
highly speciﬁc and achieves good sensitivity, including in
immunocompromised patients, but the performance strongly
depends on the experience of the microscopist. In HIV-in-
fected patients, microscopy on spleen tissue is considered to
have the highest sensitivity (Table 3) [18]. In a systematic
review by Antinori et al. [31], the sensitivity of bone marrow
microscopy was estimated to be 81% in HIV-positive patients
and 98% in transplant patients. Nevertheless, a negative bone
marrow (or spleen) aspiration ﬁnding does not completely rule
out VL, and there are several reports in which VL was
diagnosed only after repeat bone marrow examination
[110,111]. Culture can further increase sensitivity, and allows
species identiﬁcation, but can take several weeks; microculture
appears to be faster [112]. Importantly, microscopy or culture
on peripheral blood or buffy coats can also contribute to
diagnosis, with the sensitivity of microscopy of blood smear
staining estimated to be approximately 50% in HIV-infected
patients [18,113]. High parasitaemia is not common in
immunocompetent individuals in the Mediterranean endemic
areas, and should raise the suspicion of associated immuno-
suppression [114].
Serological tests for VL diagnosis, such as the indirect
ﬂuorescent antibody test, are very useful in immunocompe-
tents patients, particularly in paediatric cases [115]. In
resource-constrained settings, the direct agglutination test
and the rK39 rapid diagnostic test are most commonly used
[18]. Serological tests are clearly less reliable in HIV-infected
patients [18,116]. In Europe, they were found to present much
lower levels of Leishmania-speciﬁc serum antibodies, and >40%
of VL–HIV-co-infected patients can be negative by serology
[117]. The experience with the direct agglutination test in East
Africa seems to be better, with a sensitivity of >80% [118].
Unlike in HIV-infected patients, the diagnostic sensitivity of
serological tests in other immunocompromised patients, such
as those receiving solid organ transplants, appears to be good.
In the study by Antinori et al. [31], the sensitivity of the
indirect ﬂuorescent antibody test was estimated to be 48% in
HIV-infected patients but 93% in transplant patients. Serology
also appears to be useful for the diagnosis of VL in patients
receiving anti-TNF-a therapy [47].
Molecular diagnosis with PCR, using both bone marrow and
peripheral blood samples, is highly sensitive and speciﬁc for the
diagnosis of VL in HIV-infected patients. Furthermore, a recent
comparative study of parasitological, serological and molecular
tests for VL in HIV-infected patients demonstrated that the
sensitivity of PCR in blood samples was as good as that of
Technique Tissue/ﬂuid Immunosuppression
Sensitivity
(%) Invasiveness
Feasibility
(ﬁeld use) Reference
Microscopy Blood HIV 50 + + [18]
Spleen HIV >95 +++ + [18]
Bone marrow HIV 67–94 ++ + [18]
Lymph node HIV 53–65 ++ + [196]
Bone marrow SOT 98 ++ + [31]
Bone marrow Other 100 ++ + [85]
Culture Bone marrow HIV 70–81.3 ++ + [31,197]
SOT 82.0 ++ + [31]
Blood HIV 67 + + [113]
IFAT Serum HIV 48–75 + + [117,197]
SOT 92 + + [31]
Other 100 + + [85]
DAT Serum HIV 87.80 + ++ [198]
PCR Blood HIV 72–100 + + [121,122,
199,200]
Bone marrow HIV 82–100 ++ + [121,122,
199,200]
Latex
agglutination
test
Urine HIV 48–85.7 – ++ [124,201]
rK39 dipstick Serum HIV 46.6–93.9 + ++ [198,202]
DAT, direct agglutination test; HIV, human immunodeﬁciency virus; IFAT, indirect ﬂuorescent antibody test; SOT, solid
organ transplant.
TABLE 3. Overview of the main
diagnostic methods used and their
performance in immunosuppressed
individuals.
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direct examination of bone marrow aspirates [118]. There is
also a general consensus that PCR on blood samples is the
most useful technique for monitoring the long-term efﬁcacy of
drug therapy and for identifying relapses in treated patients,
avoiding repeated invasive procedures. Typically, conventional
Leishmania PCR on blood will become negative early after the
beginning of treatment; reappearance of a positive PCR could
indicate (or predict) relapse. With quantitative PCR, thresh-
olds have been identiﬁed, predicting the onset of symptoms
and the development of VL relapse [119–122]. Although these
have most commonly been used in HIV-infected patients, this
approach also appears to be useful in other immunosuppres-
sive conditions [31], and should probably be recommended for
monitoring treatment response in patients with immunosup-
pression.
One more option for VL diagnosis is the latex agglutination
test for the detection of leishmanial antigen in the urine.
Although this is rapid, non-invasive, and simple, the sensitivity
is low to moderate in immunocompetent individuals [123];
however, in HIV-infected patients, sensitivity up to 85.7% was
found during a primary episode of VL [124]. Although reports
are lacking, this method might also be useful for diagnosing VL
in transplanted patients.
In conclusion, taking into account the different perfor-
mances of the diagnostic tests for VL in immunocompromised
individuals, the variability of disease presentation, and the
different conditions of the patients, the best approach for
diagnosis of VL is the combination of parasitological and
serological or molecular methods, possibly to be repeated if
initial results are negative but clinical suspicion remains.
Treatment
Substantial experience has accumulated with regard to the
treatment of VL in HIV-co-infected individuals, both within and
outside Europe (mainly in Ethiopia) [18]. In general, HIV
co-infection is associated with higher initial failure and relapse
rates, more drug toxicity, and higher treatment-associated
mortality [18]. Particularly with antimonials, enhanced and
potentially life-threatening toxicity is observed in patients with
HIV co-infection. Given their excellent safety proﬁle, the
current WHO and international guidelines—mainly based on
evidence from European studies—recommend liposomal
amphotericin B as the preferred treatment (Table 4) [125–
128]. The WHO proposes a total dose of 40 mg/kg [125–127],
but lower doses might be possible in India [129]. Experience
with miltefosine is limited, with available studies suggesting
moderate efﬁcacy and an acceptable toxicity proﬁle [130–133].
Repeated VL episodes in HIV-infected patients tend to become
progressively more difﬁcult to treat, and are often associated
with poor CD4 recovery; hence, preventing VL relapse is key.
This provides the rationale for effective treatment of (primary)
VL, followed by timely initiation of HAART and secondary
prophylaxis (see below). The role of combination therapy in
patients with VL–HIV co-infection remains to be explored
TABLE 4. Treatment recommendations for leishmaniasis in immunosuppressed individuals.
Organization Target group Preferred therapy Alternative therapy
VL
American Society of Transplantation
and American Society of Transplant
Surgeons [141]
Organ transplant Liposomal amphotericin B
21 mg/kg total dose
3 mg/kg IV days 1–5, 14, 21
Amphotericin B deoxycholate 1.0 mg/kg daily for 15–20 days
or a pentavalent antimony compounda
Centers for Disease Prevention and
Control [128]
HIV Liposomal amphotericin B
20–60 mg/kg total dose
2–4 mg/kg IV daily or
interrupted schedule (e.g. 4 mg/kg days 1–5,
10, 17, 24, 31, 38)
Other amphotericin B lipid complex dosed as for liposomal
amphotericin B
Amphotericin B deoxycholate 0.5–1.0 mg/kg IV daily (total
dose of 1.5–2.0 g)
SSG 20 mg Sb5+/kg IV/IM daily for 28 days
Miltefosine 100 mg PO daily for 4 weeks
Food and Drug Administration [126] Immunosuppression
(HIV and non-HIV)
Liposomal amphotericin B
40 mg/kg total dose
3–5 mg/kg IV days 1–5, 10, 17, 24, 31, 38
WHO [127] HIV Liposomal amphotericin B
40 mg/kg total dose
3–5 mg/kg IV daily
or
days 1–5, 10, 17, 24, 31, 38
CL and MCL
American Society of Transplantation
and American Society of Transplant
Surgeons [141]
Organ transplant Pentavalent antimonialsa
20 mg Sb5+/kg IV/IM daily
CL: 21 days
MCL: 28 days
Conventional or liposomal amphotericin B, miltefosine,
paromomycin, pentamidine, and ﬂuconazole, based on
species and availability
Centers for Disease Prevention and
Control [128] (only for CL, not for
MCL/ML)
HIV Liposomal amphotericin B as for VL
SSG 20 mg Sb5+/kg IV/IM daily for 28 days
Miltefosine PO, topical paromomycin, intralesional SSG, or
local heat therapy
CL, cutaneous leishmaniasis; HIV, human immunodeﬁciency virus; IM, intramuscular; IV, intravenous; MCL, mucocutaneous leishmaniasis; PO, per os; SSG, sodium stibogluconate
(pentavalent antimony); VL, visceral leishmaniasis.
aStibogluconate or meglumine antimoniate.
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[134]. Although efﬁcacy data are lacking, many experts are in
favour of combined therapy for patients with multiple relapses.
VL is an AIDS-deﬁning condition, requiring HAART irre-
spective of CD4 counts [127]. Although there are data
suggesting that HIV-1 protease inhibitors might directly exert
inhibitory effects against Leishmania, there is insufﬁcient
evidence for their clinical use against VL, and standard HAART
regimens are currently recommended [135]. In contrast to
many other HIV-associated opportunistic infections, IRIS
appears to be relatively rare [136]. Although the widespread
use of antiretroviral treatment has resulted in dramatic
reductions in the incidence of VL–HIV co-infection, the effect
on relapse is only partial, and 1-year relapse rates of 30–60%
have been reported [18,137]. Established risk factors for VL
relapse include a previous episode of VL, low CD4 counts, and
the lack of secondary prophylaxis [138].
Most evidence regarding secondary prophylaxis stems from
retrospective observational studies in European HIV-infected
patients receiving either antimonials, lipid formulations of
amphotericin B, or pentamidine, administered every 2–
4 weeks. There is limited experience with the use of
miltefosine [132,139]. Only one small randomized controlled
trial on secondary prophylaxis has been published. In the eight
patients receiving amphotericin B lipid complex (administered
as 3 mg/kg every 3 weeks), the 1-year relapse rate was 50%.
This compared favourably with the 78% relapse rate in the nine
patients without prophylaxis [140]. Whereas maintenance
therapy is generally recommended for those at risk of VL
relapse in areas with zoonotic VL, such as Europe, this remains
controversial in areas with human-to-human transmission,
owing to the risk of rapid spread of drug resistance
[18,127,128]. Nevetheless, also in such a setting, clinicians
have used secondary prophylaxis on a case-by-case basis.
The experience with non-HIV immunosuppressive condi-
tions is more fragmented, and is mostly based on case reports
or small case series. Although no ﬁrm conclusions can be
drawn, the current data seem to suggest that initial treatment
response is better and recurrence rates are lower than in
HIV-infected individuals, but not as good as seen in the
immunocompetent population. For instance, Antinori et al.
reported an initial cure rate of 84% in transplant patients,
which was better than in HIV-infected patients (55–66%) but
not as good as in immunocompetent individuals (93–97%).
Nevertheless, mortality was substantial (15/79; 22%), although
this included ﬁve patients who did not receive VL treatment
but had the diagnosis revealed by autopsy [31]. Relatively high
rates of potentially fatal toxicity were seen with antimonials
[31,58]. Although systematic comparisons are lacking, most
authors recommend liposomal amphotericin B, because of its
good safety proﬁle [31,125,141] (Table 4). Treatment can be
complicated by overlapping toxicity and drug interactions
between some anti-leishmanial and immunosuppressive drugs
[31]. A few renal transplant patients have been successfully
treated with ﬂuconazole or ketoconazole, combined with
allopurinol [142–145]. The indications for secondary prophy-
laxis remain to be deﬁned [31,125,141], but prophylaxis has,
up to now, only been exceptionally used in patients with
non-HIV-related immunosuppression [7,31]. Perhaps surpris-
ingly, many patients remained relapse-free without mainte-
nance therapy and despite the ongoing use of
immunosuppressive medication, although dose reduction was
often instituted, at least temporarily [146].
Prevention
As there is no vaccine available for human leishmaniasis,
strategies for early detection have to be considered. Trans-
plant donor screening for leishmaniasis is currently not
suggested in most guidelines or recommendations
[74,141,147]. Serological screening of transplant recipients
with a history of potential exposure to Leishmania may be
considered before transplantation [75,141], although the
evidence base is limited [74]. Others have argued more
strongly in favour of screening prior to the initiation of
immunosuppressive treatment of any kind, proposing either
serology, skin testing or PCR as a screening tool
[28,32,37,38,148–151], possibly even at regular intervals. As
is the case for tuberculosis, Leishmania-speciﬁc interferon-c
release assays have been developed, and could be used for
screening purposes [152–156]. If an immunosuppressed indi-
vidual is known or found to be asymptomatically infected or
has a history of VL, close monitoring is warranted [74,141].
Besides regular clinical evaluation, some authors have argued
for additional regular laboratory evaluation with PCR [32].
Although pre-emptive treatment in immunosuppressed
patients has been proposed for Chagas disease [157], such
strategies have not yet been explored for VL. Primary
prophylaxis for VL in asymptomatically infected individuals
(similar to isoniazid preventive therapy in those with a positive
tuberculosis skin test result) is currently not recommended
[127]. It is of interest that, in a recent Brazilian study, none of
the liver transplant recipients who were found to be
Leishmania-PCR positive at the time of transplantation or
received a PCR-positive organ developed VL over a median
follow-up of 24 months, without any prophylaxis being given
[158]. Obviously, protective measures to prevent exposure to
sandﬂy bites are recommended for immunosuppressed indi-
viduals living in or travelling to Leishmania-endemic regions [7].
With regard to HIV-infected patients, VL screening or primary
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prophylaxis is not recommended in international guidelines
[127,128]. However, this has never been well studied, and
merits further exploration in VL-endemic areas.
CL and ML
A vast number of cases of CL and ML have been reported in
immunosuppressed individuals. Besides series of HIV-infected
patients [18,159] and transplantation cases [31,160–162],
there are also reports of reactivation of infection after
initiation of immunosuppressive drugs such as anti-TNF-a
agents [163–165] and steroids [51,166–168]. Although the
clinical presentation will often be similar to that in immuno-
competent individuals, a number of particular features have
been reported, especially in cases of severe immunosuppres-
sion. These include parasite dissemination, and clinical
polymorphism with atypical and often more severe clinical
forms [18,20,169–171]. Immunosuppression is a risk factor
for diffuse CL, an anergic form that is notorious for its poor
treatment response [76,172]. In this form, multiple nodular
lesions containing large numbers of parasites are seen
(Fig. 1). Disseminated CL, presenting with multiple pleomor-
phic lesions, is another rare form that can be seen in
immunodeﬁcient and immunocompetent individuals. ML and
MCL appear to be more common in immunosuppressed
patients [6,170,173]. Whereas MCL is typically associated
with L braziliensis, there are increasing reports of mucosal
lesions (with or without concurrent cutaneous or visceral
disease) caused by L. infantum/L. donovani, Leishmania major,
and L. tropica [6]. In several cases, isolated ML was initially
diagnosed (and treated) as malignancy or vasculitis. As in
immunocompetent individuals, diagnosis of CL and ML relies
on tissue sampling, but there is a long list of differential
diagnoses in immunosuppressed patients. Visceralization of
dermatotropic species has been reported, besides skin
dissemination of viscerotropic species [35,174,175]. There
have been reports of CL-related IRIS, with HAART unmask-
ing or exacerbating CL, in some cases with associated eye
infection [176].
As the recommended treatment of CL varies by species,
species identiﬁcation should be pursued. There are several
excellent reviews providing detailed information on the
treatment of CL, predominantly focused on immunocompe-
tent patients and/or travellers [5,125,177–181]. Given the
lack of evidence, it is unclear to what extent treatment
guidelines should differ for immunodeﬁcient individuals [163].
Especially with advanced immunosuppression, treatment
response can be poorer, with higher rates of recurrence,
and the risk of dissemination and concurrent VL and ML is
higher. Generally speaking, immunosuppression (especially if
severe) is a factor arguing in favour of systemic treatment
instead of local therapy for CL [125]. Importantly, concurrent
VL and ML will have to be looked for. The evidence base for
the treatment of ML and MCL is limited, and this is even
more the case for immunosuppressed individuals. Although
some cases of isolated ML have been successfully treated
with local treatment, most authors argue in favour of
systemic treatment for ML, given the risk of subsequent
visceralization [173,182]. Table 4 summarizes some recent
recommendations.
Conclusion
Both HIV-related and non-HIV-related immunosuppression
pose signiﬁcant challenges for the diagnosis and management of
VL and, to a lesser extent, CL. Whereas HIV-associated VL
was reported frequently in southern Europe before the
introduction of HAART, VL is now more often seen in
patients with non-HIV-related immunosuppression. As not all
cases are reported or notiﬁed, the current burden of
leishmaniasis in immunosuppressed individuals is probably
underestimated. At the global level, the burden of both
HIV-related and non-HIV-related immunosuppressive leish-
maniasis will probably continue to rise, owing to globally
increased travel and access to advanced medical care. This
warrants increased attention and enhanced surveillance
FIG. 1. Diffuse cutaneous leishmaniasis in a transplant patient, caused
by Leishmania infantum acquired in Spain.
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systems. Early diagnosis will require increased awareness
among the medical community across various disciplines, and
the wide availability of or access to accurate diagnostic tools.
The value and cost-effectiveness of screening and prophylactic
treatment merits further research.
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